The content on this site is intended for healthcare professionals only
CheckMate 459: Long-term survival outcomes with nivolumab versus sorafenib as fi...
Prof Bruno Sangro - University of Navarra, Pamplona, Spain
15 Jul 2020
Phase I/II results: First-line NALIRIFOX in patients with pancreatic ductal aden...
Dr Zev Wainberg - Ronald Reagan UCLA Medical Center, Los Angeles, USA
8 Jul 2020
Early safety from a trial of talimogene laherparepvec (T-VEC) injected into live...
Prof J. Randy Hecht - UCLA Jonsson Comprehensive Cancer Center, Santa Monica, US...
17 Jun 2020
Perioperative chemotherapy with mFOLFIRINOX vs gemcitabine/nab-paclitaxel for re...
Prof Davendra Sohal - University of Cincinnati, Cincinnati, USA
15 Jun 2020
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
12 Jun 2020
Highlights from ASCO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
5 Jun 2020
The potential of KRAS inhibitors for non-small-cell lung cancer
Prof Reinhard Büttner - University Hospital Cologne, Cologne, Germany
22 Apr 2020
NIVOREN: Nivolumab in a 'real world setting' for metastatic clear-cell renal cel...
Dr Yann-Alexandre Vano - Hôpital Européen Georges-Pompidou, Paris, France
18 Feb 2020
Surgical treatment of cholangiocarcinoma and liver metastases
Dr. Amit Mathur, Mayo Clinic, Rochester, USA
21 Oct 2019
Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA
4 Oct 2019
CheckMate 459: Safety and efficacy of nivolumab versus sorafenib as a first-line...
Dr Thomas Yau - The University of Hong Kong, Hong Kong
4 Oct 2019
Health-related quality of life for patients with metastatic pancreatic cancer: U...
Prof Eric Van Cutsem and Dr Teresa Macarulla
2 Oct 2019